


Trimega Laboratories Limited

Directors' report and financial statements

31 January 2007

Registered in England and Wales number 05652830



Trimega Laboratories Limited

Directors' report and financial statements

Contents

	Page
Directors' report	1
Statement of directors' responsibilities in respect of the Directors' Report and the financial statements	2
Profit and loss account	3
Balance sheet	4
Notes	5 - 10

Trimega Laboratories Limited

Directors' report

The directors submit their first report for the period from 13 December 2005 to 31 January 2007

Incorporation date

The company was incorporated on 13 December 2005 in England and Wales

Change in accounting reference date

The Company changed its accounting reference date from 31 December to 31 March on 19 January 2006. The Company further changed its accounting reference from 31 March to 31 January on 12 January 2007.

Principal activities

The focus of the Company is to provide technical testing and analysis services to identify drug and alcohol use to agencies in the criminal justice, legal and healthcare sectors. The directors foresee no material change in the nature of the Company's activities.

Financial review and dividends

The results for the period are set out in the profit and loss account on page 3. The directors do not recommend the payment of a dividend.

Directors

The directors who held office during the period were as follows:

A B Lasarow (appointed 13 December 2005)

Dr A Semikhodskii (appointed 10 January 2006)

Statement of directors' responsibilities in respect of the Directors' Report and the financial statements

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations

The report of the directors has been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies

Company law requires the directors to prepare financial statements for each financial period. Under that law they have elected to prepare the financial statements in accordance with UK Accounting Standards and applicable law (UK Generally Accepted Accounting Practice)

The financial statements are required by law to give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period

In preparing those financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgements and estimates that are reasonable and prudent,
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements, and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business

The directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 1985. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities

This report was approved by the board on DATE



20/12/07

K Katavich
Company Secretary

10 New Square
Lincoln's Inn
London
WC2A 3QG
DATE

Trimega Laboratories Limited

Profit and loss account

for the period thirteen month period from 13 December 2005 to 31 January 2007

	Note	For the period 13 December 2005 to 31 January 2007 £
Sales	2	146,709
Cost of sales		(26,742)
Gross profit		119,967
Sales and marketing costs	3	(71,438)
Administration expenses	4	(148,014)
Sundry income		1,170
Operating loss before interest and taxation		(98,315)
Other interest receivable and similar income	5	12
Interest payable and similar charges	6	(3,201)
Loss on ordinary activities before taxation		(101,504)
Tax on loss on ordinary activities	7	-
Loss for the financial period	13	(101,504)

All results are derived from continuing activities

There was no recognised gains and losses other than the loss for the period

There is no difference between the results as stated and their historical cost equivalents

Trimega Laboratories Limited

Balance sheet
at 31 January 2007

	Note		31 January 2007 £
Fixed assets			
Tangible assets	8		254
Intangible assets	9		200
			<hr/>
Current assets			454
Debtors	10		
Cash at bank and in hand		62,487 1,251	
		<hr/>	
Creditors amounts falling due within one year	11	63,738 (165,596)	
		<hr/>	
Net current liabilities			(101,858)
			<hr/>
Net liabilities			(101,404)
			<hr/>
Capital and reserves	12		
Called up share capital	12		100
Profit and loss account	13		(101,504)
			<hr/>
Equity shareholders' funds	14		(101,404)
			<hr/>

These financial statements were approved by the board of directors on
on its behalf by

2007 and were signed



20/9/07

A Lasarow
Director

Trimega Laboratories Limited

Notes

(forming part of the financial statements)

1 Accounting policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the financial statements, except as noted below

Basis of preparation

The financial statements have been prepared in accordance with applicable accounting standards and under the historical cost accounting rules

Turnover

Turnover represents the invoiced amount of good sold and services provided less returns and allowances excluding value added tax. Income received in advance of the provision of good and services is held in deferred income within the balance sheet until those goods or services have been provided

Taxation

The charge for taxation is based on the profit for the period and takes into account taxation deferred because of timing differences between the treatment of certain items for taxation and accounting purposes

Deferred tax is recognised without discounting, in respect of all timing differences between the treatment of certain items for taxation and accounting purposes which have arisen but not reversed by the balance sheet date, except as otherwise required by FRS 19

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less accumulated depreciation

Depreciation is calculated to write down the cost less estimated residual value of all tangible fixed assets over their expected useful lives. The principal annual rates and method used are

Computer equipment 33% straight line

Foreign currency transactions

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of the exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit

Trimega Laboratories Limited

Notes (continued)

(forming part of the financial statements)

Classification of financial instruments issued by the Company

Financial instruments issued by the Company are treated as equity (i.e. forming part of shareholders' funds) only to the extent that they meet the following two conditions

- a) they include no contractual obligations upon the Company to deliver cash or other financial assets or to exchange financial assets or financial liabilities with another party under conditions that are potentially unfavourable to the Company and
- b) where the instrument will or may be settled in the Company's own equity instruments, it is either a non-derivative that includes no obligation to deliver a variable number of the Company's own equity instruments or is a derivative that will be settled by the Company's exchanging a fixed amount of cash or other financial assets for a fixed number of its own equity instruments

To the extent that this definition is not met, the proceeds of issue are classified as a financial liability. Where the instrument so classified takes the legal form of the Company's own shares, the amounts presented in these financial statements for called up share capital and share premium account exclude amounts in relation to those shares

Finance payments associated with financial liabilities are dealt with as part of interest payable and similar charges

Trimega Laboratories Limited

Notes (continued)

2 Turnover

Gross sales
Sales discount

For the period 13
December 2005 to
31 January 2007
£

149,625
(2,916)

146,709

3 Sales and marketing costs

Accommodation
Marketing expenses
Telesales
Training costs
Travelling expenses

For the period 13
December 2005 to
31 January 2007
£

576
7,682
48,040
2,692
12,448

71,438

4 Administrative expenses

Accountancy and audit
Administration expenses
Depreciation
Legal fees
Professional Fees
Rent
Directors expenses
Other

For the period 13
December 2005 to
31 January 2007
£

1,325
24,160
11
6,921
50,408
13,996
45,000
6,193

148,014

5 Other interest receivable and similar income

Bank interest received

For the period 13
December 2005 to
31 January 2007
£

12

Trimega Laboratories Limited

Notes (continued)

6 Interest payable and similar charges

	For the period 13 December 2005 to 31 January 2007 £
Bank interest	600
Other	2,601
	<hr/>
	3,201
	<hr/>

7 Tax on loss on ordinary activities

	For the period 13 December 2005 to 31 January 2007 £
Analysis of credit in the period	
Corporation tax for the period	
	<hr/>
Total current tax	-
	<hr/>

Factors affecting the tax credit for the period

The current tax credit for the period is lower than the standard rate of corporation tax in the UK of 30%.

The differences are explained below.

	For the period 13 December 2005 to 31 January 2007 £
Current tax reconciliation	
Loss on ordinary activities before taxation	(101,604)
	<hr/>
Current tax at 30%	(30,451)
Effects of:	
Adjustments to tax charge in respect of previous periods	
	<hr/>
Current tax credit for the period	(30,451)
	<hr/>

Trimega Laboratories Limited

Notes (continued)

8 Tangible fixed assets

	31 January 2007
	£
Computer equipment	
Cost	
Depreciation	265
	(11)
At 31 March 2007	
	254

9 Intangible fixed assets

	31 January 2007
	£
Patent	
Cost	200
At 31 March 2007	
	200

10 Debtors

	31 January 2007
	£
Trade debtors	62,487

11 Creditors amounts falling due within one year

	31 January 2007
	£
Trade creditors	
Taxation and social security	28,428
Lloyds factoring account	8,219
Other creditors	44,149
	84,800
	165,596

Trimega Laboratories Limited

Notes (continued)

12 Called up share capital

31 January 2007

£

Authorised, allotted, called up and fully paid

1 000 Ordinary shares of £0.01

100

13 Profit and loss account

Profit and
loss account
£

Loss for the financial period

(101,504)

At 31 January 2007

(101,504)

14 Reconciliation of movements in equity shareholders' funds

31 January 2007

£

Loss for the financial period

(101,504)

Issue of new share capital

100

Net movement in shareholders' funds

(101,404)

Closing shareholders' funds

(101,404)

15 Related party transactions

Max ASP GmbH has a 10% share holding in the company. Max ASP provides telesales services to the company. During the period, the total amount of telesales services paid was £48,040.

Cash flow statement

The financial statements do not include a cash flow statement because the company, as a small reporting entity, is exempt from the requirements to prepare such a statement under the Financial Reporting Standard or Smaller Entities (effective January 2005).